Filtered By:
Cancer: Carcinoma
Vaccination: Cervical Cancer Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 147 results found since Jan 2013.
Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance
CONCLUSIONS: TTMV-HPV DNA surveillance testing yields few false negative results and few missed recurrences. These data could inform decisions on when to pursue re-imaging following first disease restaging and could inform future surveillance practice. Additional study of how pre-treatment TTMV-HPV DNA status impacts sensitivity for recurrence is needed.PMID:37566241 | DOI:10.1158/1078-0432.CCR-23-1478
Source: Cell Research - August 11, 2023 Category: Cytology Authors: Glenn J Hanna Scott A Roof James Jabalee Eleni M Rettig Rocco Ferrandino Sida Chen Marshall R Posner Krzysztof J Misiukiewicz Eric M Genden Raymond L Chai John Sims Elaine Thrash Scott J Stern Noah S Kalman Sreenija Yarlagadda Adam Raben Lydia Clements Ab Source Type: research
Etiology, diagnosis, treatment, and prevention of human papilloma virus-associated oropharyngeal squamous cell carcinoma
Int J Clin Oncol. 2023 Apr 24. doi: 10.1007/s10147-023-02336-8. Online ahead of print.ABSTRACTClassical oropharyngeal squamous cell carcinoma (OPSCC) caused by alcohol consumption and smoking and HPV-associated OPSCC caused by human papillomavirus (HPV) infection have different etiologies, incidences, and prognoses. Therefore, the 8th American Joint committee on Cancer (AJCC) and Union for International Cancer Control (UICC) TNM classifications propose distinguishing HPV-associated OPSCC from classical OPSCC and classifying it as an independent disease. Therefore, this review provides an overview of HPV-associated OPSCC fr...
Source: Cancer Control - April 24, 2023 Category: Cancer & Oncology Authors: Hirotaka Shinomiya Ken-Ichi Nibu Source Type: research
Early effect of bivalent human papillomavirus vaccination on cytology outcomes in cervical samples among young women in the Netherlands
CONCLUSIONS: By linking nation-wide registries on pathology and vaccination, we show significant beneficial early effects of HPV-vaccination on LSIL, HSIL+, CIN3/AIS/carcinoma and hrHPV detection in young women upto 24 years of age who have a cervical sample taken before entry into the cervical cancer screening program.PMID:36965085 | DOI:10.1002/cam4.5842
Source: Cancer Control - March 25, 2023 Category: Cancer & Oncology Authors: Tessa M Schurink-van 't Klooster Albert G Siebers Joske Hoes Folkert J van Kemenade Johannes Berkhof Johannes A Bogaards Hester E de Melker Source Type: research
Highlights into historical and current immune interventions for cancer
Int Immunopharmacol. 2023 Feb 27;117:109882. doi: 10.1016/j.intimp.2023.109882. Online ahead of print.ABSTRACTImmunotherapy is an additional pillar when combined with traditional standards of care such as chemotherapy, radiotherapy, and surgery for cancer patients. It has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapies, including adoptive cellular therapy (ACT) and checkpoint inhibitors (CPIs), can induce durable clinical responses. However, their efficacies vary, and only subsets of cancer patients benefit from their use. In this review, we address three goal...
Source: International Immunopharmacology - February 27, 2023 Category: Allergy & Immunology Authors: Kathryn Cole Zaid Al-Kadhimi James E Talmadge Source Type: research
The relationship of human papillomavirus positivity with tumor characteristics in an Irish penile cancer population
CONCLUSIONS: Our data is representative of the Irish landscape in penile cancer over the last five years. Using p16INK4a staining, we demonstrate a high rate of HPV prevalence in penile cancer cases in our patient cohort, which is associated with prognostically worse tumor subtypes. This would suggest that HPV vaccination of adolescent boys is a useful public health intervention in preventing penile cancer in the Irish male population.PMID:36656691 | PMC:PMC9851216 | DOI:10.5489/cuaj.7821
Source: Canadian Urological Association Journal - January 19, 2023 Category: Urology & Nephrology Authors: Eva Browne Megan Power Foley John O'Kelly Aisling Nic An R íogh Nigam Shah Christine Shilling John P Keane Padraig Daly Ivor M Cullen Source Type: research
Safety and Efficacy of MEDI0457 Plus Durvalumab in Patients With Human Papillomavirus-associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
CONCLUSIONS: MEDI0457 plus durvalumab was well tolerated. While the primary efficacy endpoint was not reached, clinical benefit was encouraging.PMID:36455147 | DOI:10.1158/1078-0432.CCR-22-1987
Source: Clinical Cancer Research - December 1, 2022 Category: Cancer & Oncology Authors: Charu Aggarwal Nabil F Saba Alain Algazi Ammar Sukari Tanguy Y Seiwert Missak Haigentz Mercedes Porosnicu Marcelo Bonomi Jean Boyer Mark T Esser Lily I Cheng Sonia Agrawal Emily C Jennings Nicholas M Durham Karl Fraser Delphine Lissa Maozhen Gong Natalia Source Type: research
